28 Dec 2023 • Does testosterone replacement therapy in men with hypogonadism increase the risk of high-grade or any prostate cancer or other adverse prostate events?

• Middle-aged and older men treated with testosterone replacement therapy (TRT) for hypogonadism didn't experience an increase in adverse prostate events, as found in the TRAVERSE trial.
• Incidences of high-grade or any prostate cancer, acute urinary retention, invasive surgical procedures, prostate biopsy, and new pharmacologic treatment were low and did not significantly differ between the TRT and placebo groups.

The findings provide valuable insights for a more informed evaluation of the potential risks associated with testosterone replacement therapy.

Source: JAMA | Read full story